On 10 March 2026, the Polish Patent Office, after examining an invalidation request filed by Egis Pharmaceuticals PLC, issued a decision invalidating in its entirety patent PL204263, which constitutes the Polish counterpart of patent EP1427415, the basic patent protecting apixaban.

The ground for invalidation was lack of inventive step.

Although this decision is not yet final and may be appealed to the Voivodeship Administrative Court, it appears likely that it will ultimately determine the availability of the Polish market for generic products containing apixaban.

We congratulate Egis and are pleased that we were able to represent the company in these proceedings.